Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...

2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.

The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter rotation trade continues to gather steam during the last whole trading week ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Treatment with Kisunla was associated with sustained clinical benefits, specifically less symptom worsening and significant amyloid clearance up to 3 years, in early symptomatic Alzheimer’s disease, ...

The Brown County Community Foundation is pleased to announce the recipient of the 2026 Lilly Endowment Community Scholarship ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

U.S. lawsuits against Novo Nordisk and Eli Lilly alleging patients taking weight loss drugs lost some or all of their ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...